Corpus Intelligence IC Memo — ST. ALPHONSUS MEDICAL CENTER - NAMP 2026-04-26 06:42 UTC
IC Memo — ST. ALPHONSUS MEDICAL CENTER - NAMP
Investment Committee Memorandum | ID | 96 beds | Grade C | EBITDA uplift $19.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

ST. ALPHONSUS MEDICAL CENTER - NAMP

CCN 130013 | CANYON, ID | 96 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

ST. ALPHONSUS MEDICAL CENTER - NAMP is a 96-bed suburban community hospital in CANYON, ID with $263.3M in net patient revenue and a 15.2% operating margin. The hospital serves a payer mix of 24.1% Medicare, 23.3% Medicaid, and 52.6% commercial.

Thesis: Turnaround. Our ML models identify $19.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 15.2% to 22.6% (+736bps).

Net Revenue HCRIS$263.3M
Current EBITDA COMPUTED$40.0M
Operating Margin COMPUTED15.2%
Occupancy HCRIS78.7%
Revenue / Bed COMPUTED$2.7M
Net-to-Gross HCRIS32.6%
Distress Probability ML44.1%

2. Market Context & Competitive Position

51
ID Hospitals
-3.5%
State Median Margin
10
Comparable Hospitals

ID has 51 Medicare-certified hospitals with a median operating margin of -3.5%. The target's margin of 15.2% places it above the state median. Among 10 size-comparable peers (48-192 beds), the median margin is -1.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (48-192), prioritizing same-state peers. 10 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ST. ALPHONSUS MEDICAL CENTER - (Target)ID96$263.3M15.2%
ST LUKES MAGIC VALLEY REG MED ID175$482.9M-6.8%
PORTNEUF MEDICAL CENTERID142$390.3M13.4%
ST. LUKES NAMPA MEDICAL CENTERID87$255.6M-10.1%
ST JOSEPH REGIONAL MEDICAL CENID110$168.4M-3.0%
WEST VALLEY MEDICAL CENTERID112$118.1M24.6%
IDAHO FALLS COMMUNITY HOSPITALID88$98.9M-23.1%
MADISON MEMORIAL HOSPITALID53$94.0M1.1%
INTERMOUNTAINID150$31.5M26.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $19.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.5M+210bp18mo
Cost to Collect4.5%2.5%$5.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$5.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.2M+122bp9mo
Clean Claim Rate88.0%96.0%$169K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.5M
Cost to Collect
$5.3M
Denial Rate Reduction
$5.2M
A/R Days Reduction
$3.2M
Clean Claim Rate
$169K
Total EBITDA Uplift$19.4M
Current EBITDA$40.0M
+ RCM Uplift+$19.4M
Pro Forma EBITDA$59.4M
Current Margin15.2%
Pro Forma Margin22.6%
WC Released (1x)$10.1M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$61.6M$457.8M7.44x49.4%
Base (11x exit)10.0x11.0x$61.6M$523.6M8.50x53.4%
Bull Case9.0x11.0x$55.4M$607.5M10.96x61.4%
Bull (12x exit)9.0x12.0x$55.4M$679.1M12.26x65.1%
Bear Case11.0x10.0x$67.7M$340.9M5.03x38.2%
Bear (11x exit)11.0x11.0x$67.7M$397.0M5.86x42.4%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (23.3%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 10 hospitals with 48-192 beds
  • Same-state prioritization (n=11)
  • Comp margins: P25=-9.3% / P50=-1.0% / P75=13.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.